- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04678817
Same Day Oral EC and Implant Initiation
A Prospective Observational Study of Preference for and Efficacy of Oral Levonorgestrel Emergency Contraception With Same Day Etonogestrel Contraceptive Implant Compared to Established Pregnancy Rates With Oral Levonorgestrel Emergency Contraception Alone
Study Overview
Status
Conditions
Detailed Description
Recommended options for EC include oral EC (levonorgestrel (LNG), ulipristal acetate (UPA), or combination oral contraceptive pills), or the copper intrauterine device (IUD). Recent data will also allow women presenting for EC to be offered the LNG IUD. These recommendations leave out the only other long-acting reversible contraceptive (LARC), the ENG implant. Current guidelines allow for same-day ENG implant initiation at the time of an EC encounter, as long as oral LNG EC is co-administered. We lack data on pregnancy risk for the EC-eligible population desiring same-day ENG implant placement and oral EC.
Women presenting for EC often need ongoing contraception, but clinical practice is not standardized in same-day counseling and initiation due to system, provider, and client-level barriers. Interest in LARC use continues to increase as well as same-day contraception initiation at the time of an EC encounter. Women presenting for EC may not have considered LARC options before. Generating estimates and continuation rates for same-day initiation with an EC encounter will improve contraceptive options for women seeking EC.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Corinne Sexsmith
- Phone Number: 801-213-2522
- Email: corinne.sexsmith@hsc.utah.edu
Study Contact Backup
- Name: Marie Gibson
- Phone Number: 801-213-2845
- Email: marie.gibson@hsc.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84102
- Planned Parenthood Association of Utah
-
West Valley City, Utah, United States, 84119
- Planned Parenthood Association of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy women
- Age 18-35 years
- Fluent in English and/or Spanish
- BMI < 30 kg/m2
- No known contraindication to either the ENG contraceptive implant or oral LNG EC using the CDC Medical Eligibility Criteria for Contraceptive Use 2016
- Negative urine pregnancy test
- Willing to abstain from further UPI in the 7 days following insertion
- Know the date of their last menstrual period
- Regular menstrual cycle (24-35 days)
- Be willing to comply with the study requirements
- Desiring to avoid pregnancy for at least 12 months
Exclusion Criteria:
- Current pregnancy or breastfeeding
- Previous use of oral EC in the current cycle
- Report of UPI beyond 5 days in current cycle
- Vaginal bleeding of unknown etiology
- Allergy to LNG or ENG, IUD or implant in-place
- History of permanent contraception through sterilization or hysterectomy
- Monogamous partner with a vasectomy
- Depo-provera injection within past 15 weeks
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy rate at one-month
Time Frame: one month
|
To determine a point estimate for the one-month pregnancy rate following guideline supported same-day initiation of an etonogestrel (ENG) implant plus oral levonorgestrel (LNG) emergency contraception (EC).
|
one month
|
Comparing Proportions of EC clients desiring ENG implant with oral EC vs IUD
Time Frame: 2 years
|
To determine the proportion of EC clients willing to initiate a same-day ENG implant with oral LNG EC compared to same-day initiation of intrauterine devices for EC.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Continuation Rates
Time Frame: 6 and 12 months
|
6- and 12-month continuation rates of the ENG implant with same-day initiation at an EC encounter.
|
6 and 12 months
|
Discontinuation Timing and Reasons
Time Frame: 12 months
|
Timing and reasons for ENG implant discontinuation in the 12 months following same-day initiation at an EC encounter.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lori Gawron, MD, University of Utah
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 137011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States